Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-08-14), BioNTech SE's 3-1 Month Momentum % is -0.21%.
The industry rank for BioNTech SE's 3-1 Month Momentum % or its related term are showing as below:
BSP:B1NT34's 3-1 Month Momentum % is ranked better than 61.31% of 1388
companies
in the Biotechnology industry
Industry Median: -8.13
vs BSP:B1NT34: -0.21
BioNTech SE (BSP:B1NT34) 3-1 Month Momentum % Explanation
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
BioNTech SE 3-1 Month Momentum % Related Terms
BSP:B1NT34 vs INSM, INCY, MRNA: 3-1 Month Momentum % Comparison
For the Biotechnology subindustry, BioNTech SE's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioNTech SE 3-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioNTech SE's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where BioNTech SE's 3-1 Month Momentum % falls into.
BioNTech SE (BSP:B1NT34) 3-1 Month Momentum % Calculation
3-1 Month Momentum % is calculated as following:
3-1 Month Momentum %
=
( Price 1-month ago
/
Price 3-month ago
- 1 )
*
100 %
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioNTech SE (BSP:B1NT34) has a 3-1 Month Momentum % of -0.21% as of Aug. 14, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on BioNTech SE and its competitors. According to the industry distribution chart, BioNTech SE ranks #537 out of 1388 companies in the Biotechnology industry, placing it in the top 38.7%.
Is BioNTech SE's 3-1 Month Momentum % too high?
BioNTech SE's current 3-1 Month Momentum % is -0.21%. Based on the distribution chart, BioNTech SE ranks #537 out of 1388 companies in the Biotechnology industry, which is above the industry midpoint. Overall, BioNTech SE has a GF Score™ of 49/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does BioNTech SE's 3-1 Month Momentum % compare to INSM and INCY?
According to the Biotechnology industry distribution chart, BioNTech SE ranks #537 out of 1388 companies for 3-1 Month Momentum %. This puts BioNTech SE in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
A good 3-1 Month Momentum % depends on the Biotechnology industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on BioNTech SE and its competitors. BioNTech SE's current 3-1 Month Momentum % is -0.21%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioNTech SE stock overvalued right now?
Based on GuruFocus' analysis, BioNTech SE (BSP:B1NT34) is currently considered Fairly Valued. The stock's GF Value™ is R$27.30, compared to a current price of R$29.79 — trading 9.1% above its estimated fair value. The current 3-1 Month Momentum % is -0.21%. BioNTech SE's overall GF Score™ is 49/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For BioNTech SE (BSP:B1NT34), the current 3-1 Month Momentum % is -0.21% as of Aug. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioNTech SE (BSP:B1NT34) Overvalued in 2026?
Based on GuruFocus' analysis, BioNTech SE stock appears to be overvalued.
The current stock price of R$29.79 is trading 9.1% above its estimated GF Value™ of R$27.30.
GuruFocus considers BioNTech SE to be Fairly Valued.
Key valuation signals for BSP:B1NT34:
3-1 Month Momentum %: -0.21%
GF Value™: R$27.30 vs. price of R$29.79 (9.1% above fair value)
No single metric tells the full story. See the BSP:B1NT34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens and neoantigens; monospecific and bispecific antibodies; and antibody-drug conjugates, or ADCs. Comirnaty, its Pfizer-partnered covid vaccine, is its first commercialized product.
49GF Score
Get the complete analysis for BSP:B1NT34
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSP:B1NT34 has been successfully added to your 
